Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 1700 of 2529 entries
View as:
Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer
Phase: N/A
Priority: Normal
Start: 12/26/18
End: 09/07/20
Due: 09/07/21
Phase: N/A
Priority: Normal
Start: 03/31/13
End: 03/31/15
Due: 03/31/16
Phase: N/A
Priority: Normal
Start: 04/30/03
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 09/30/11
End: 02/29/12
Due: 02/28/13
Phase: N/A
Priority: Normal
Start: 05/31/11
End: 05/31/11
Due: 05/31/12
Phase: N/A
Priority: Normal
Start: 08/16/13
End: 02/10/20
Due: 02/10/21
Phase: N/A
Priority: Normal
Start: 09/30/11
End: 02/28/15
Due: 02/28/16
Phase: N/A
Priority: Normal
Start: 03/31/15
End: 01/18/17
Due: 01/18/18
Phase: N/A
Priority: Normal
Start: 07/31/00
End: 06/30/04
Due: 06/30/05
Phase: N/A
Priority: Normal
Start: 02/29/12
End: 06/30/12
Due: 06/30/13
Phase: N/A
Priority: Normal
Start: 11/05/14
End: 01/17/17
Due: 01/17/18
Phase: N/A
Priority: Normal
Start: 12/31/04
End: 07/31/09
Due: 07/31/10
Phase: N/A
Priority: Normal
Start: 01/14/19
End: 01/28/20
Due: 01/28/21
Phase: N/A
Priority: Normal
Start: 11/30/07
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 12/01/20
End: 12/23/21
Due: 12/23/22
Phase: N/A
Priority: Normal
Start: 07/17/14
End: 01/30/17
Due: 01/30/18
Phase: N/A
Priority: Normal
Start: 12/09/16
End: 02/26/21
Due: 02/26/22
Phase: N/A
Priority: Normal
Start: 02/28/06
End: 11/16/10
Due: 11/16/11
Phase: N/A
Priority: Normal
Start: 01/31/12
End: 05/31/13
Due: 05/31/14
Phase: N/A
Priority: Normal
Start: 07/31/13
End: 09/30/14
Due: 09/30/15
Phase: N/A
Priority: Normal
Start: 08/13/04
End: 07/08/13
Due: 07/08/14
Phase: N/A
Priority: Normal
Start: 05/31/03
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 01/13/15
End: 11/10/20
Due: 11/10/21
Phase: N/A
Priority: Normal
Start: 10/15/13
End: 02/23/22
Due: 02/23/23
Phase: N/A
Priority: Normal
Start: 04/19/16
End: 04/24/17
Due: 04/24/18